Premium
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases
Author(s) -
Koulova Lydia,
Alexandrescu Doru,
Dutcher Janice P.,
O'Boyle Kevin P.,
Eapen Saji,
Wiernik Peter H.
Publication year - 2005
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20243
Subject(s) - medicine , rituximab , thrombocytopenic purpura , plasmapheresis , thrombotic thrombocytopenic purpura , splenectomy , refractory (planetary science) , gastroenterology , concomitant , platelet , surgery , immunology , antibody , spleen , physics , astrobiology
Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti‐CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not respond to steroids and anti‐D antibody administration achieved augmentation of her platelet counts up to 180 × 10 3 /μL after four doses of rituximab. Six months later, when her counts started to decrease, she received maintenance therapy with an additional course of 4 standard doses of antibody that resulted in consolidation of her platelet counts around 100 × 10 3 /μL. One patient with TTP and concurrent idiopathic nephropathy who was previously treated with plasmapheresis, steroids, and vincristine improved only after 4 weekly administrations of the antibody. Moreover, his nephrotic‐range proteinuria resolved after he received rituximab. The other patient with chronic TTP who still relapsed after splenectomy received 5 doses of rituximab with concomitant plasmapheresis. His thrombocytopenia improved slowly, and his platelet count stabilized at 300 × 10 3 /μL. All three patients showed evidence of response to anti‐CD20 antibody with improvement in clinical outcome as well as augmentation of platelet counts to normal levels. We conclude that rituximab is a useful immunomodulating adjunct in the treatment of refractory ITP and TTP. Am. J. Hematol. 78:49–54, 2005. © 2004 Wiley‐Liss, Inc.